Enveric Biosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, disclosing a net loss of $2,549,354 for the third quarter and total assets of $6,371,370.

Key Highlights

  • Net loss (Q3 2026): $2,549,354, compared to $1,873,669 in Q3 2025, according to the filing.
  • Nine-month net loss: $7,210,560 for the nine months ended September 30, 2026, versus $6,577,816 for the same period in 2025.
  • Total assets: $6,371,370 as of September 30, 2026, up from $5,095,941 at December 31, 2025.
  • Cash position: $5,612,988 as of September 30, 2026, compared to $4,677,491 at December 31, 2025.
  • Shares outstanding: 4,475,884 shares of common stock as of November 11, 2026, up from 1,061,533 at December 31, 2025.
  • Accumulated deficit: $122,057,052 as of September 30, 2026, compared to $114,846,492 at December 31, 2025.
  • Research and development expenses increased to $1,354,889 in Q3 2026 from $402,417 in Q3 2025, the filing reported.

Enveric Biosciences' Financial Position and Operations Through September 30, 2026

According to the filing, Enveric Biosciences (NASDAQ:ENVB) reported total operating expenses of $2,564,088 for the three months ended September 30, 2026, compared to $1,873,943 for the same period in 2025. The increase was driven primarily by higher research and development costs, which rose to $1,354,889 in Q3 2026 from $402,417 in Q3 2025. General and administrative expenses declined to $1,174,280 from $1,431,157 over the same comparison period, the filing stated.

For the nine months ended September 30, 2026, the registrant reported total operating expenses of $7,224,699, up from $6,580,525 in the prior-year period. The net loss per share on a basic and diluted basis was $0.57 for Q3 2026, compared to $10.81 for Q3 2025, with weighted average shares outstanding rising substantially to 4,483,762 from 313,242, reflecting equity issuances during the period. The filing disclosed that the company raised capital through a private placement and registered direct offering in Q1 2026, netting $1,144,027 after offering costs of $368,990, and through an at-the-market agreement netting $1,291,038 after costs of $54,484. A further private placement in Q2 2026 raised net proceeds of $4,408,738 after offering costs of $814,085.

As of September 30, 2026, total shareholders' equity stood at $5,727,168, up from $4,177,541 at December 31, 2025. Total current liabilities decreased to $644,202 from $918,400, the filing noted. The company classified itself as a non-accelerated filer and smaller reporting company. The filing indicated that as of the date of the report, 4,475,884 shares of common stock with a par value of $0.01 per share were outstanding.

What Was Disclosed

Enveric Biosciences filed its quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $2,549,354, increased R&D spending, a cash balance of $5,612,988, and significant share count growth from equity offerings and warrant exercises during the nine-month period.